Core Insights - The article discusses the concept of "Black Swan" events, which are unpredictable and have significant impacts, as exemplified by Nassim Nicholas Taleb's experiences during the 1987 stock market crash [8][10][26] - Taleb's investment philosophy emphasizes the importance of recognizing uncertainty and leveraging it to create opportunities, rather than attempting to predict specific outcomes [26] Group 1: Taleb's Background and Philosophy - Nassim Nicholas Taleb was born in Lebanon and experienced the instability of the Lebanese Civil War, which shaped his understanding of risk and uncertainty [4][5] - His fascination with options trading stems from their non-linear nature, where limited losses can lead to disproportionate gains, reflecting the hidden dangers in seemingly safe situations [5][6] - Taleb's successful bet on deep out-of-the-money put options during the 1987 crash illustrates his ability to capitalize on extreme events that others deemed impossible [2][3] Group 2: Key Concepts in Taleb's Framework - The concept of "Black Swan" refers to rare events that are unpredictable but can be rationalized in hindsight, such as financial crises and pandemics [8][10] - Taleb introduces the idea of "Antifragility," which describes systems that benefit from chaos and volatility, contrasting with fragile systems that break under stress [11][26] - The "Barbell Strategy" is proposed, where 85-90% of resources are allocated to extremely safe investments, while 10-15% are placed in high-risk, high-reward opportunities, avoiding the mediocre middle ground [12][11] Group 3: Practical Applications and Challenges - Taleb emphasizes the principle of "Skin in the Game," advocating that decision-makers should bear the consequences of their choices, enhancing accountability [13] - The investment strategy employed by Taleb and his followers involves consistently purchasing cheap deep out-of-the-money options, which may lead to short-term losses but can yield substantial returns during market crashes [15][17] - The psychological challenge of maintaining patience and resisting the urge to conform to prevailing market trends is highlighted, as investors often struggle with the discomfort of short-term losses [17][19]

LingBot-VLA凭借扎实的基座能力，大幅降低了下游任务的适配门槛，仅需80条演示数据即可实现高质 量的任务迁移。此外，配合底层代码库的深度优化，其训练效率达到StarVLA、OpenPI等主流框架的 1.5~2.8倍，实现了数据与算力成本的双重降低。 此次开源不仅提供了模型权重，还同步开放了包含数据处理、高效微调及自动化评估在内的全套代码 库。这一举措大幅压缩了模型训练周期，降低了商业化落地的算力与时间门槛，助力开发者以更低成本 快速适配自有场景，模型实用性大幅提升。 长期以来，由于本体差异、任务差异、环境差异等，具身智能模型落地面临严重的泛化性挑战。开发者 往往需要针对不同硬件和不同任务重复采集大量数据进行后训练，直接抬高了落地成本，也使行业难以 形成可规模化复制的交付路径。 针对上述问题，LingBot-VLA基于20000+小时大规模真机数据进行预训练，覆盖了9种主流双臂机器人 构型(包括AgileX，Galaxea R1Pro、R1Lite、AgiBot G1等)，从而让同一个"大脑"可以无缝迁移至不同构 型的机器人，并在任务变化、环境变化时保持可用的成功率与鲁棒性。与高精度空间感知模型Ling ...

（成都先导公告） 公告指出，业绩变化的主要原因包括主营业务的稳健增长和新技术业务板块的商业转化逐步显现。核心 业务板块DEL保持稳步增长，英国子公司的FBDD/SBDD平台也取得了阶段性进展。此外，公司的非经 营性损益方面，公允价值变动损失同比减少，主要系交易性金融负债公允价值变动影响减少所致。 近日，成都先导发布公告称，预计2025年年度实现归母净利润为1.04亿元至1.29亿元，与上年同期相 比，将增加5264万元至7564万元，同比增加102.50%至147.29%；预计归母净利润扣除非经常性损益后 为1.06亿元至1.29亿元，与上年同期相比，将增加4856万元至7156万元，同比增加84.55%至124.59%。 ...

近日，上海弼领生物技术有限公司（以下简称"弼领生物"）完成超2亿元B轮融资。本轮融资由宏诚投 资及关联方（阳光诺和、弘曜科创）与涌铧投资联合领投，泰达科投、中科创星跟投，老股东龙磐投资 和泰煜投资持续加码，丰和资本担任本轮融资独家财务顾问。 此次募集资金将重点用于核心临床管线的快速推进、早期创新项目的研发迭代及跨学科核心团队的扩 充，进一步巩固公司在纳米偶联药物领域的全球技术领先地位，加速突破性疗法的临床转化与商业化布 局。 （弼领生物公众号） ...

近日，中国中药发布公告称，预计2025年本集团将由盈转亏，亏损净额区间预估约为3.5亿元至5亿元， 而上年同期的盈利净额约为2077万元。同时，本期经调整盈利净额预计同比下降45%至55%，上年同期 约为6.36亿元。 董事会表示，上述事项不会对本集团的持续经营能力产生不利影响，并强调所提及的经调整盈利净额并 未在香港财务报告准则中界定。股东及潜在投资者应注意本公告所载信息为初步评估，最终业绩公告预 计于2026年3月底前发布。 亏损的主要原因包括中药配方颗粒业务收入规模及盈利能力下降。此外，本期商誉减值、无形资产减值 及信用减值增加。 （中国中药公告） (编辑：杨燕 林辰) ...

作为靶向PCSK9的小干扰RNA降胆固醇药物，英克司兰钠注射液一年两针的给药方式，有望提升治疗 依从性及LDL-C的长期达标率，助力实现血脂的长期规范化管理。 （诺华公众号） 1月28日，诺华在其公众号宣布，其创新性降胆固醇药物乐可为 （英克司兰钠注射液）获中国国家药品 监督管理局批准，作为饮食的辅助疗法，单药用于成人原发性高胆固醇血症（非家族性）或混合型血脂 异常的患者，以降低低密度脂蛋白胆固醇（LDL-C）。 这意味着英克司兰钠注射液在此前已获批的与他汀类药物、或者与他汀类药物及其他降脂疗法联合用药 适应症的基础上，进一步覆盖了更多有需要的血脂异常患者。 ...

公开资料显示，易方达黄金主题LOF主要通过投资全球市场的黄金ETF及黄金采掘公司股票实现资产配 置，其中投资于基金的资产比例不低于基金资产净值的60%，且80%以上投向黄金基金。 1月28日，易方达基金管理有限公司发布公告称，今日起暂停A类人民币份额的申购及定期定额投资业 务，赎回业务照常办理，A类人民币份额恢复办理申购、定期定额投资业务的时间将另行公告。 ...

业绩减亏因公司拓展市场，阿达木单抗、托珠单抗销售额提升，乌司奴单抗在美国上市，授权许可及销 售收入增长。 近日，百奥泰发布公告称，预计 2025 年度实现归属于母公司所有者的净利润与上年同期相比，将减少 亏损，实现归属于母公司所有者的净利润为-28,000.00 万元到-39,000.00 万元，减少亏损 12,030.38 万元 到 23,030.38 万元。 （百奥泰公告） ...

Core Viewpoint - He Eye Hospital (301103) expects a net profit attributable to shareholders of 24 million to 36 million for 2025, representing a year-on-year growth of 187.60% to 231.40% [1] Group 1: Performance Improvement - The company has achieved a turnaround from loss to profit during the reporting period, driven by business structure optimization, effective cost control, and the disposal of inefficient assets [1] - Significant enhancement in profitability is attributed to the continuous optimization of the business structure, with a focus on high-margin refractive and optical businesses [1] Group 2: Cost and Efficiency Management - The company has implemented refined operational management, achieving cost reduction and efficiency improvement through centralized procurement optimization, supply chain efficiency enhancement, and digital operations [1] - These measures have contributed to the overall improvement in profitability [1] Group 3: Asset Optimization - The company has actively integrated, adjusted, or divested certain business units that have long-term poor performance or weak strategic synergy, further optimizing asset allocation efficiency [1]

1月27日，北京农商银行发布公告称， 该行董事会于近日收到董事长关文杰提交的书面辞职报告。因工作原因，关文杰辞去该行董事长、董事、董事会战略 与可持续发展委员会主任委员及三农金融服务委员会（乡村振兴金融服务委员会）主任委员职务。关文杰的辞任自2026年1月21日起生效。经关文杰确认， 其与该行董事会无不同意见，亦无任何与其辞任有关的事项需要通知该行股东及债权人。 （北京农商银行） ...